| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.0073 | 0.9 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.9 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.9 |